Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001984047 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 12/23/2025 false 0001598646 603380106 MINERVA NEUROSCIENCES, INC. 1500 District Avenue Burlington MA 01803 Boehringer Ingelheim Int. GmbH 49613277171954 Binger Strasse 173 Attn: Head of Corp. Legal Gov. and M&A Ingelheim am Rhein 2M 55216 0001984047 N Boehringer AG b WC N 2M 0 1500225 0 1500225 1500225 N 3.4 CO (1) Securities reflected in rows 8, 10 and 11 comprised of 1,275,000 shares of Common Stock (as defined herein) and an additional 225,225 shares of Common Stock receivable upon exercise of a Pre-Funded Warrant (as defined herein). All securities are held directly by Boehringer Ingelheim International GmbH ("International GmbH"), a wholly owned indirect subsidiary of C. H. Boehringer Sohn AG & Co. KG ("Parent"). Boehringer AG (the "GP") is the General Partner of Parent. The GP and International GmbH may each be deemed to have shared voting and dispositive power over all of the securities. (2) Percentage in row 13 based on (i) 43,274,398 shares of Common Stock issued and outstanding as of December 23, 2025, as reported by Minerva Neurosciences, Inc. (the "Issuer") in its Registration Statement on Form S-3 filed on December 23, 2025 and (ii) 225,225 shares of Common Stock issuable within 60 days of the date hereof upon the exercise of a Pre-Funded Warrant held by International GmbH. Y Boehringer Ingelheim International GmbH b WC N 2M 0 1500225 0 1500225 1500225 N 3.4 CO (1) Securities reflected in rows 8, 10 and 11 comprised of 1,275,000 shares of Common Stock and an additional 225,225 shares of Common Stock receivable upon exercise of a Pre-Funded Warrant. All securities are held directly by International GmbH, a wholly owned indirect subsidiary of Parent. The GP is the General Partner of Parent. The GP and International GmbH may each be deemed to have shared voting and dispositive power over all of the securities. (2) Percentage in row 13 based on (i) 43,274,398 shares of Common Stock issued and outstanding as of December 23, 2025, as reported by the Issuer in its Registration Statement on Form S-3 filed on December 23, 2025 and (ii) 225,225 shares of Common Stock issuable within 60 days of the date hereof upon the exercise of a Pre-Funded Warrant held by International GmbH. Common Stock, par value $0.0001 per share MINERVA NEUROSCIENCES, INC. 1500 District Avenue Burlington MA 01803 This Amendment No. 1 ("Amendment No. 1") amends as set forth below a statement on Schedule 13D filed by the Reporting Persons (as defined herein) on July 7, 2023 (the "Original Filing") with respect to shares of Common Stock and a pre-funded warrant to purchase the same (the "Pre-Funded Warrant"). On December 23, 2025, each of the Reporting Persons ceased to be a beneficial owner of more than 5% of the Common Stock as a result in the increase in the shares of Common Stock outstanding. The filing of this Amendment No. 1 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Persons. This Amendment No. 1 is being filed on behalf of each of the following persons (each a "Reporting Person" and, together, the "Reporting Persons"): (i) Boehringer AG, a stock corporation (Aktiengesellschaft) organized under the laws of the Federal Republic of Germany (the "GP"); and (ii) Boehringer Ingelheim International GmbH, a limited liability company (Gesellschaft mit beschrankter Haftung) organized under the laws of the Federal Republic of Germany ("International GmbH"). The principal business address of each of the GP and International GmbH is Binger Strasse 173, 55216 Ingelheim am Rhein, Germany. There are no material updates to the Original Filing. During the last five years, neither of the Reporting Persons nor any person named in Schedule I (consisting of the members of the Board of Managers and Supervisory Board of the GP and of the Board of Managers of International GmbH) has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). During the last five years, neither of the Reporting Persons nor any person named in Schedule I has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, as a result of which, he, she or it was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. Each of the Reporting Persons is organized under the laws of the Federal Republic of Germany. There are no material updates to the Original Filing. There are no material updates to the Original Filing. GP 1,500,225 3.4% International GmbH 1,500,225 3.4% (i) Sole power to vote or to direct the vote GP 0 International GmbH 0 (ii) Shared power to vote or to direct the vote GP 1,500,225 International GmbH 1,500,225 (iii) Sole power to dispose or to direct the disposition of GP 0 International GmbH 0 (iv) Shared power to dispose or to direct the disposition of GP 1,500,225 International GmbH 1,500,225 International GmbH is a wholly owned indirect subsidiary of C. H. Boehringer Sohn AG & Co. KG ("Parent"). The GP is the General Partner of Parent. The GP and International GmbH may each be deemed to have shared voting and dispositive power over all of the securities. None of the individuals listed on Schedule I beneficially own any Common Stock. Neither the Reporting Persons nor any of the individuals listed on Schedule I have effected any transactions in the Common Stock during the past sixty days. The decrease in percentage of beneficial ownership reported in this Amendment No. 1 results solely from an increase in the number of outstanding shares of Common Stock. Not applicable December 23, 2025 There are no material updates to the Original Filing. There are no material updates to the Original Filing. Boehringer AG /s/ Arjan van der Oort Arjan van der Oort, Registered Manager (Prokurist) 12/30/2025 /s/ Martin Bergmann Martin Bergmann, Registered Manager (Prokurist) 12/30/2025 Boehringer Ingelheim International GmbH /s/ Dana Leskova Dana Leskova, Registered Manager (Prokurist) 12/30/2025 /s/ Dr. Martin Schwarz Dr. Martin Schwarz, Registered Manager (Prokurist) 12/30/2025